Free NewsletterPro Login

Warning: Undefined variable $stocks in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: Undefined variable $funds in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472
/* the link was here */
×
Free investor livestream — Nov 17

How To Use ChatGPT & Claude To Research Stocks Like A Pro

01
The prompt we use to break down any stock
02
How to fact-check what AI tells you
03
How to compare two stocks in minutes

Denmark awards DKK 15 million to 31 patients after rare eye condition reported post-Novo weight-loss use

Published Nov 19, 2026
Share:
Summary:
  • Denmark has disbursed DKK 15 million (about $2.2 million) to 31 individuals diagnosed with a rare, serious eye condition following use of Novo Nordisk's weight-loss drugs.
  • Of 94 claims related to Wegovy or Ozempic, 29 were turned down while 34 remain under review, Danish Patient Compensation said.
  • The FDA now mandates a class-wide warning on GLP-1 drugs about possible increased risk of NAION, a form of optic nerve damage.

The payouts and the pipeline of claims

Authorities in Denmark have compensated 31 patients with a total of DKK 15 million, roughly $2.2 million, after they developed a rare eye condition following use of Novo Nordisk's weight-loss treatments. Claims run through Danish Patient Compensation, an independent group funded by the state and insurers.

Ninety-four people who believe they experienced the side effect after using Wegovy or Ozempic have submitted claims. Of those, 29 were declined and 34 await decisions. Denmark, a country of about 6 million people, started awarding compensation for NAION cases last year.

Safety scrutiny and company response

Novo Nordisk and Eli Lilly are under heightened scrutiny over a potential side effect that can cause permanent vision loss. In 2024, Denmark's medicines regulator was the first to alert European authorities to a possible link, making the country an early test case.

US regulators have acted too. Doctors have said patients should be told about the possible risk.

When headlines raise questions about risks and rules, sign up for the free Market Briefs newsletter for a quick daily update

Novo Nordisk says it does not see a cause-and-effect relationship between its medicines and the eye condition, while acknowledging the impact on patients and families. "We remain confident in the benefit-risk profile of our GLP-1 medicines," a spokesperson said by email.

How Denmark structures compensation

Payments come from the Danish state, not from Novo. Because Denmark's public health system covers most medical treatment, awards generally emphasize harms like diminished earning capacity and lasting injury rather than hospital expenses.

NAION occurs when reduced blood flow injures the optic nerve. It is rare, most often affects people over 50, cannot be treated, does not reverse, and can lead to blindness.

What this means for your portfolio

For GLP-1 makers, the direction of risk is on the label and in the headlines. Watch how the 34 pending Danish cases are resolved and whether other regulators mirror the FDA's class-wide warning, since that can influence demand, litigation exposure, and long-run margins for both Novo Nordisk and Eli Lilly.

Good decisions start with clear context, so get the free Market Briefs in your inbox for a short daily take

Disclosure

Recent News

1 2 3 … 131

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

November 17, 2026
Is the Stock Market Going to Crash? Why Nvidia and the Fed Have Investors on Edge
  • Tech stocks are selling off because investors don't know who will lead Nvidia, the company that has been funding the AI industry and selling it chips.
  • Inflation has the Federal Reserve planning to raise interest rates, with a hike expected in December, and that puts pressure on homebuyers, private equity and the $40 trillion national debt.
  • Briefs Finance CEO Jaspreet Singh says nobody has a crystal ball, so his rules are to buy when markets are low, hold long term and invest only what you're willing to lose.
Read More
November 16, 2026
The $40 Trillion National Debt: Trump's 4-Part Plan to Make It Feel Smaller
  • The national debt is above $40 trillion, and the Federal Reserve has gone from sending Washington its profits to losing money.
  • President Trump's four-part plan leans on shorter-term debt, stablecoin companies buying Treasuries, a bigger balance sheet and government stakes in private companies.
  • The goal is to outgrow the debt, not pay it off, so Jaspreet Singh points investors to the seven industries where Washington wants growth.
Read More
November 16, 2026
The Fed Is Talking About a Jumbo Interest Rate Hike. It Has No Easy Way Out
  • The Fed makes its next rate decision on December 9 and is now talking about jumbo interest rate hikes of 0.5%, though one in December looks unlikely.
  • Washington will pay a record $1.05 trillion in interest this year on $40 trillion of debt, and that debt resets at higher rates as the Fed hikes.
  • Jaspreet Singh's five moves are to pay down variable-rate debt, earn interest on your savings, know which stocks feel the pressure, look at value and hedge.
Read More
November 16, 2026
Buying on Margin Is at a Record High. Here's the Risk for the Stock Market
  • Margin debt, the money investors borrow to buy stocks, is at a record of around 4.6% of GDP, up from 3.9% in 2021.
  • ETF money has more than tripled in five years to 7% of GDP, while corporate buybacks and 401(k) money sit below their earlier peaks.
  • Margin calls and panic selling can make the next downturn deeper, so Jaspreet Singh keeps buying broad market funds and says most investors should skip margin debt.
Read More
November 16, 2026
Housing Prices Are Falling. Buying a House Still Isn't Cheaper
  • Housing prices have fallen for four straight weeks, but mortgage rates around 7.2% keep the monthly payment about where it was in 2023.
  • Talk of a jumbo Fed rate hike and a plan to sell Fannie Mae and Freddie Mac on the stock market could both push mortgage rates higher.
  • Briefs Finance CEO Jaspreet Singh treats a house as a liability: buy within your budget and let your investments build the wealth.
Read More
November 14, 2026
Nvidia News: Jensen Huang Is Out, and the "Bank" Behind American AI Just Lost Its Founder
  • Jensen Huang is out at Nvidia over affairs with multiple people, and the company he founded has been the bank of American AI, with about $30 billion into OpenAI and $10 billion into Anthropic.
  • A hotter-than-expected inflation report has Fed officials talking about a possible 0.5% hike in December, and gold, silver, and bitcoin fell on the news.
  • President Trump said the US may not need a deal with Iran, keeping oil prices and inflation risk high. Jaspreet Singh breaks down what it all means for AI stocks and your portfolio.
Read More
November 14, 2026
Record Highs, a 57-Year Low in Jobless Claims, and a Stock Market Bubble: Inside the Weirdest Market in History
  • Stocks are booming at the fastest pace in years, jobless claims just hit a 57-year low, and most investors still feel like nobody is hiring.
  • The Fed is protecting the dollar over the economy, oil swings on every Iran headline, and a few AI companies are carrying an S&P 500 where four of five stocks sit in a correction.
  • Jaspreet Singh explains why circular financing between Nvidia, OpenAI, Anthropic, and SpaceX rhymes with 2008's house of cards, and how his three investing pillars handle a stock market bubble.
Read More
November 14, 2026
Is a Recession Coming? The Fed Just Made a U-Turn It Has Only Made Twice in 60 Years
  • The Fed has raised rates, cut them, then raised them again only twice in the last 60 years, and both times the economy fell into a recession and stocks crashed.
  • The same stop-and-go cycle is playing out now, with one big difference: US debt is 125% of GDP today versus about 30% in 1980.
  • In the 1970s gold rose roughly 24x, real estate 157%, stocks lagged, and cash lost half its value. Jaspreet Singh lays out five assets to consider before the next flip.
Read More
November 14, 2026
The 2027 Tax Brackets Are Out: How Some Investors Can Earn $135,300 and Pay $0
  • The IRS 2027 tax plan keeps the same seven rates but widens every bracket and lifts the married-filing-jointly standard deduction to $33,200.
  • The 0% long-term capital gains bracket rises to $102,100, so a household living on $135,300 of investment income could owe $0 in federal income tax.
  • C corporations still pay 21%, small businesses keep the 20% QBI deduction, and the 401(k) limit climbs to $25,500 with an $8,500 catch-up for investors over 50.
Read More
November 14, 2026
Rare Earth Stocks: Why China's January 2027 Ban Could Be the Opportunity of the Decade
  • China plans to block rare earth exports to the US on January 10, 2027, and the US produces effectively zero of the 17 metals that go into phones, cars, dishwashers, and missiles.
  • When China cut off Japan in 2010 and squeezed Germany from 2015, some rare earth prices jumped 18x and 15x, and one rare earth company went bankrupt while another soared.
  • Washington is already putting billions into MP Materials, Vulcan, and a stockpile called Project Vault, and Jaspreet Singh walks through how investors can get exposure to rare earth stocks and ETFs.
Read More
1 2 3 … 33
Share via
Copy link